Immatics (IMTX) FCF Margin (2019 - 2026)

Immatics (IMTX) posted FCF Margin of 291.96% for Q4 2025, up 65.28% sequentially from 840.85% in Q3 2025, and down 19099.0% YoY from N/an in Q4 2024.

Analysis

Immatics (IMTX) FCF Margin (2019 - 2026) Analysis & Trends

Immatics has reported FCF Margin for 7 years, with the latest figure at 291.96% in Q4 2025.

Quarterly FCF Margin fell 19099.0% year-over-year to 291.96% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 358.48% (down 26775.0% YoY) and the FY2025 annual result came in at 352.36%, down 26139.0% from the prior year.
FCF Margin rose to 291.96% in Q4 2025 per IMTX's latest filing, from 840.85% in the prior quarter.
Over five years, FCF Margin peaked at 285.75% in Q2 2022 and troughed at 840.85% in Q3 2025.
A 5-year average of 192.04% and a median of 157.16% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2022 and 2025: FCF Margin jumped 64416 bps in 2022, then tumbled 77968 bps in 2025.
Over 5 years, FCF Margin stood at 149.0% in 2021, then increased by 28 bps to 107.78% in 2022, then surged by 256 bps to 168.16% in 2023, then plunged by 160 bps to 100.98% in 2024, then sank by 189 bps to 291.96% in 2025.
According to Business Quant data, FCF Margin over the past three periods registered 291.96%, 840.85%, and 794.32% for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	13.35%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-388.28%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	25.68%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	22.62%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	70.82%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-22.35%
10	Immatics	1.17 Bn	711.21 Mn	-	-651.68%

Historic Data

Download Data